Systems and methods for delivering an implantable device

Information

  • Patent Grant
  • 12295584
  • Patent Number
    12,295,584
  • Date Filed
    Wednesday, December 6, 2023
    a year ago
  • Date Issued
    Tuesday, May 13, 2025
    10 days ago
Abstract
A method of preparing a ventricular partitioning device for implantation using a delivery system can include coupling the ventricular partitioning device to a delivery catheter, loading the ventricular partitioning device and a portion of the delivery catheter into a sleeve and creating a liquid-tight seal between a portion of the sleeve and the delivery catheter, coupling a distal end of the sleeve to a guide catheter, and delivering fluid through at least one of the first fluid delivery port or the second fluid delivery port. The method can be performed with the delivery catheter or the sleeve having a first fluid delivery port positioned thereon. The method can be with the guide catheter having a second fluid delivery port positioned thereon.
Description
INCORPORATION BY REFERENCE

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.


TECHNICAL FIELD

This invention relates to the field of ventricular devices useful for treating cardiac dysfunction.


BACKGROUND

Congestive heart failure (CHF) is a chronic medical condition in which the heart progressively enlarges. The enlarged heart cannot deliver sufficient oxygenated and nutrient rich blood to the body's cells, CHF is commonly associated with left ventricular dysfunction and/or diastolic dysfunction. Left ventricular dysfunction results from impaired emptying of the left ventricular heart chamber, in contrast, diastolic dysfunction refers to alterations in left ventricular properties that adversely affect ventricular filling and diastolic pressure.


A key aspect of normal diastolic filling is the contribution of left ventricular elastic recoil forces to left ventricular filling. Elastic recoil is the ability of the stretched heart to return to its resting position. For example, in a healthy heart, the end-diastolic dimension of the left ventricle may range from 36-56 mm (relaxed) and the end-systolic dimension of the left ventricle may range from 20-40 mm (contracted). A left ventricle in heart failure would typically have larger dimensions than those of a healthy heart. Elastic recoil forces are important in early diastole because they allow rapid and enhanced early filling by assisting the expansion of the left ventricle.


In the case of heart enlargement and/or a decrease in myocardial function, elastic recoil forces may be reduced or absent, thus ceasing to assist early ventricular filling and leading to an increase of the ventricular filling pressure. For example, a patient experiencing CHF typically has an ejection fraction of 40% or less.


Thus, there is a need for a new and useful system, device, and method for treating cardiac dysfunction. This invention provides such a new and useful system, device, and method.


SUMMARY

The present disclosure is directed to systems and methods for implantable device delivery. One aspect of the disclosure is directed to a delivery system for an implantable device. In some embodiments, a delivery system for an implantable device includes a delivery catheter including a tubular body having a proximal end and a distal end; a sleeve defining a lumen configured to receive the delivery catheter and the implantable device coupled thereto; a first fluid delivery port positioned on the delivery catheter or the sleeve; a mechanical seal coupled to the sleeve and configured to form a liquid-tight seal with the delivery catheter; and a guide catheter comprising a tubular body having a proximal end, a distal end, and a second fluid delivery port positioned thereon.


In some embodiments, the distal end of the delivery catheter is configured to couple to the implantable device. In some embodiments, the proximal end of the guide catheter is configured to be connected to a distal end of the sleeve. In some embodiments, the guide catheter includes a hemostatic valve positioned at the proximal end of the guide catheter.


In some embodiments, a first pressure in the guide catheter is greater than a second pressure in a ventricle when fluid is delivered through the guide catheter. In some embodiments, the system includes a pressurized fluid reservoir. In one embodiment, the pressurized fluid reservoir is configured to be in fluid communication with the delivery catheter. In some embodiments, the system includes a pump. In one embodiment, the pump is configured to deliver fluid through the delivery catheter.


In some embodiments, the mechanical seal is a gasket.


In some embodiments, the implantable device is a ventricular partitioning device. In one embodiment, the implantable device includes a support frame including a plurality of radially expandable struts and a membrane coupled to the support frame. In one embodiment, the implantable device includes a foot for contacting a first interior wall portion of the ventricle.


In some embodiments, the first pressure in the guide catheter is about 200-600 mm Hg. In some embodiments, the second pressure in the ventricle is about 50-300 mm Hg.


In some embodiments, the fluid is delivered at a positive pressure into the first and/or second fluid delivery ports.


In some embodiments, the system includes a funnel. In one embodiment, the funnel includes a flared first end and a second end. In one embodiment, the flared first end is configured for receiving and collapsing the expandable device. In one embodiment, the second end of the funnel is coupleable to the sleeve.


One aspect of the disclosure is directed to methods of preparing a ventricular partitioning device for implantation. In some embodiments, a method of preparing a ventricular partitioning device for implantation using a delivery system includes coupling the ventricular partitioning device to a delivery catheter; loading the ventricular partitioning device and a portion of the delivery catheter into a sleeve and creating a liquid-tight seal between a portion of the sleeve and the delivery catheter; coupling a distal end of the sleeve to a guide catheter; and delivering fluid through the first fluid delivery port and/or the second fluid delivery port.


In some embodiments, the delivery catheter or the sleeve includes a first fluid delivery port positioned thereon. In some embodiments, the guide catheter includes a second fluid delivery port positioned thereon.


In some embodiments, the step of delivering the fluid creates a first pressure in the guide catheter that is greater than a second pressure in a ventricle.


In some embodiments, the method includes transferring the ventricular partitioning device from the sleeve to the guide catheter. In some embodiments, the method includes delivering the ventricular partitioning device from the guide catheter into the ventricle. In some embodiments, the method includes uncoupling the delivery catheter from the ventricular partitioning device.


In some embodiments, the method includes loading the ventricular partitioning device into a funnel device. In one embodiment, the funnel device includes a flared first end and a second end.


In one embodiment, the flared first end is configured for receiving and collapsing the expandable device.


In some embodiments, the sleeve is removably coupled to the second end of the funnel device. In one embodiment, the sleeve is configured for receiving the expandable device from the funnel device.


In some embodiments, the delivering fluid step includes delivering the fluid at a positive pressure. In some embodiments, the method includes maintaining the positive pressure in the guide catheter during delivery of the ventricular partitioning device into the ventricle.


In some embodiments, the first pressure in the guide catheter is about 200-600 mm Hg. In some embodiments, the second pressure in the ventricle is about 50-300 mm Hg.


In some embodiments, the method includes aspirating gas from the delivery system through the second fluid delivery port while fluid is delivered through the first fluid delivery port.


In some embodiments, the method includes removing bubbles from the delivery system using the first and/or second fluid delivery ports.


In some embodiments, the method includes allowing blood to exit the delivery system through the second fluid delivery port disposed on the guide catheter as the ventricular partitioning device is advanced from the sleeve into the guide catheter.


In some embodiments, delivering fluid through the first fluid delivery port and/or the second fluid delivery port includes delivering fluid through the first fluid delivery port into the guide catheter as the ventricular partitioning device is advanced through the guide catheter.


In some embodiments, the fluid is substantially maintained in the delivery system by the liquid-tight seal.


In some embodiments, the method includes sealing the second fluid delivery port disposed on the guide catheter at a time after the ventricular partitioning device has advanced distally beyond the second fluid delivery port.


In some embodiments, the delivering fluid step includes delivering the fluid using a pump at a flow rate between about 0.5 to 5 mL/second.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates one embodiment of a ventricular partitioning device;



FIGS. 2A-2D illustrate one embodiment of a foot of a ventricular partitioning device;



FIGS. 3A-3C illustrate an alternative embodiment of a foot of a ventricular partitioning device;



FIGS. 4A-4C illustrate one embodiment of a stem for coupling a membrane to a foot of a ventricular partitioning device;



FIGS. 5A and 5B illustrate a top and side view of one embodiment of a membrane coupled to a support frame of a ventricular partitioning device, respectively;



FIGS. 6A-6C illustrate two embodiments of the struts of a ventricular partitioning device;



FIGS. 7A-7D illustrate one embodiment of a support frame;



FIGS. 8A-8D illustrate an exterior view of one embodiment of an implant loading system for a ventricular partitioning device;



FIGS. 9A-9C illustrate a cross-sectional view of one embodiment of an implant loading system for a ventricular partitioning device;



FIGS. 10A-10D illustrates an alternative embodiment of an implant loading system for a ventricular partitioning device;



FIG. 11 illustrates one embodiment of a delivery catheter coupled to a ventricular partitioning device;



FIG. 12A illustrates one embodiment of a delivery catheter;



FIG. 12B illustrates one embodiment of a delivery system;



FIGS. 12C-12E illustrate one embodiment of a gasket;



FIG. 12F illustrates one embodiment of a hemostatic valve;



FIG. 13 illustrates one embodiment of a delivery catheter positioned in a guide catheter;



FIG. 14 illustrates another embodiment of a delivery system;



FIG. 15A illustrates one embodiment of guide catheter comprising two hemostatic valves;



FIG. 15B illustrates one embodiment of a delivery catheter inserted into a guide catheter through two hemostatic valves; and



FIG. 16 provides a flow chart depicting one embodiment of a method of preparing a ventricular partitioning device for implantation using a delivery system.





DETAILED DESCRIPTION

Disclosed herein are systems and devices for treating cardiac dysfunction. In some instances, cardiac dysfunction may include diastolic dysfunction, mitral valve regurgitation, and/or heart failure.


In general, the systems and devices described herein may be used to treat a patient's heart suffering from heart failure. The systems and devices may be used to treat a patient's heart experiencing diastolic dysfunction or a condition exhibiting characteristics of diastolic dysfunction, and may involve implanting, within a ventricle of the heart, a device that partitions the ventricle into functional and nonfunctional portions. In some embodiments, the device may deform during systole and recoil during diastole to supplement the natural elastic recoil action of the ventricle. In some embodiments, the device may reduce the end-diastolic volume, end-diastolic pressure, and/or increase the ejection fraction.


Diastole represents the period of time in the heart cycle in which the ventricles are relaxed and not contracting. Throughout most of diastole, blood is passively flowing from the right and left atria into the right and left ventricles, respectively. As the ventricles begin to contract, the pressure in the ventricles exceeds that of the atria, and the mitral valve closes, ending diastole. At this time, the ventricular pressure and volume are referred to as end-diastolic pressure and end-diastolic volume, respectively.


Reduced ventricular compliance, for example due to an increased stiffness in the ventricular heart wall, may result in increased end-diastolic pressure and decreased end-diastolic volume. Diastolic dysfunction may also result from changes in left ventricle relaxation during diastole. For example, inotropic stimulation, fast heart rates, non-uniform heart activation, and altered timing of forces that oppose ventricular ejection may contribute to altered left ventricle relaxation.


Devices



FIG. 1 illustrates an expandable or implantable device, which may also be referred to as a ventricular partitioning device, 1 to treat cardiac dysfunction. In some embodiments, cardiac dysfunction may include diastolic dysfunction, mitral valve regurgitation, heart failure, and/or any other type of malady of the heart. The device may be delivered to the ventricle of a patient to treat cardiac dysfunction. In some embodiments, as shown in FIG. 1, a device for treating cardiac dysfunction may include a foot 2 for contacting a first interior wall portion of a heart. Further, in some embodiments, a device for treating cardiac dysfunction may include a support frame 3 including a plurality of radially expandable struts 4 and a membrane 5 coupled to the support frame 3. Each of the radially expandable struts 4 has a first free end 4a and a second end 4b coupled to the foot 2.



FIGS. 2A-2D and 3A-3C illustrate two embodiments of a foot 2 coupled to a stem 6 of an expandable device. The foot 2 of a ventricular partitioning device may contact an interior wall portion of a heart of a patient experiencing cardiac dysfunction. An interior wall portion of a heart may include an apex of a ventricle. In some embodiments, the foot 2 may contact the apex of the ventricle so that the entire device is underneath the papillary muscle located in the ventricle, such that the ventricular partitioning device does not interfere with the heart valve in the apex of the ventricle. In some embodiments, the foot 2 may contact the apex of the ventricle atraumatically such that the apex of the ventricle does not incur damage, trauma, and/or significant injury.


The foot 2 of the device, as shown in FIGS. 2A3C, is supportive such that it does not collapse upon itself once implanted. However, the foot 2 may also be flexible, such that the device does not create focal pressure points (e.g., “hot spots”) in the ventricle. To balance these properties of the ventricular partitioning device, the foot 2 of the ventricular partitioning device may include a thermoplastic elastomer. In some embodiments, the foot 2 may include thermoplastic silicone polyether polyurethane (TPU), such as DSM.


In some embodiments, as shown in FIGS. 2A-3C, the foot 2 may include a different material and/or durometer than the stem. In some embodiments, the foot 2 may include, Pursil TSPU, or any other thermoplastic material, such that the durometer is 70 A to 90 A and the flexural modulus or bending modulus is 15 MPa to 45 MPa. In one embodiment, the foot includes a durometer of 78 A to 84 A and a flexural modulus or bending modulus of 20 MPa to 40 MPa. In some embodiments, the stem 6 may include elasthane TPU, or any other thermoplastic material, such that the durometer is 45 D to 75 D and the flexural modulus or bending modulus is 100 MPa to 400 MPa. In one embodiment, the stem includes a durometer of 50 D to 70 D and a flexural modulus or bending modulus of 145 MPa to 390 MPa.


In some embodiments, the foot 2 of the ventricular partitioning device may include a radiopaque filler material to aid in visualization of the implant during and/or after implantation of the ventricular partitioning device in the heart of a patient. In some embodiments, the foot 2 may include 20% radiopaque filler. Alternatively, the foot 2 and stem 6 may include 40% radiopaque filler or any other percent of radiopaque filler suitable to the application. For example, the foot 2 and/or stem 6 may include between about 10 and 50% radiopaque filler, or at least about 10, 20, 30, or 40% radiopaque filler.


In some embodiments, as shown in FIGS. 2C and 3C, the foot 2 may have a height H ranging from 0.5 mm to 4.0 mm and a diameter D ranging from 13 mm to 17 mm, depending on the distance between the apex of the ventricle and the papillary muscle in the ventricle. In some embodiments, the foot 2 of the ventricular partitioning device may comprise a plurality of sections or petals 7. In some embodiments, a foot 2 may include 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 petals. In one embodiment, the foot 2 includes 5 petals, as shown in FIGS. 2A, 2B, 3A, and 3C. The petals 7 may include a looped configuration such that each petal includes an aperture 7a. Alternatively, the petals may comprise a solid configuration. Each petal 7 may be coupled to at least two other petals 7 of the foot 2 of the ventricular partitioning device. Alternatively, each petal 7 of the foot 2 may be separate and uncoupled from the other petals 7 of the foot 2. In some embodiments, the foot may alternatively include a screw for securing the ventricular partitioning device to the apex, a hub, or any other component suitable for positioning a ventricular partitioning device in a heart.


In some embodiments, as shown in FIGS. 2A, 2C, and 2D, the petals 7 of the foot 2 may be curved or include an angled portion 8, such that the point of attachment 9 of the petals 7 to the stem 6 is held at a distance from the apex of the ventricle while the perimeter 10 of the petals 7 is contacting the apex of the ventricle, as shown in FIGS. 2A and 2B. Alternatively, as shown in FIGS. 3A and 3C, the petals 7 may be coupled to the stem 6 at a right angle (90°) to the stem 6, such that the entire perimeter 10 and/or surface area of the petals 7 of the foot 2 may contact the apex of the ventricle.


In some embodiments, as shown in FIGS. 3A-3C, the foot 2 may be used in a ventricular partitioning device for treating acute myocardial infarction in order to prevent cardiac remodeling or damage (configured as an endocardial implant). In this embodiment, the device is configured to be positioned immediately adjacent to the heart wall, for example similar to a patch, across from the region of the infarct.



FIGS. 2A-3C illustrate a stem 6 coupled to a foot 2 of a ventricular partitioning device, such that the stem 6 is configured to receive a support frame of a ventricular partitioning device, as shown in FIG. 1. In some embodiments, the stem 6 may be substantially rigid for coupling to the support frame. However, the stem 6 may also be flexible for increasing the elastic recoil force of the ventricular partitioning device. The stem 6, as shown in FIGS. 4A-4C, may include a base 11 and a shaft 12 for receiving a support frame. In some embodiments, as shown in FIG. 4A, the base 11 may include a flange 11a to create a strong bond between the stem 6 and the foot 2 of the ventricular partitioning device. For example, the petals of the foot may be injection molded around the base of the stem and flange. Alternatively, in some embodiments, the stem 6 may be coupled to the foot 2 by another mechanism, for example by screwing, soldering, sintering, snapping, locking, fastening, or any other type of reversible or irreversible coupling mechanism.



FIGS. 4B-4C illustrate a cross-section of a stem 6 of a ventricular partitioning device in accordance with a preferred embodiment. The stem 6 may serve as an interface between the foot 2 and the support frame 3 of the ventricular partitioning device. As shown in FIG. 4C, the foot 2 may be secured to the support frame 3 by a cross pin 13 or any other type of fastener. For example, the hub or shaft at the base of the support frame may slide into the shaft 12 of the stem 6, such that a pin 13 may be inserted through the cross-section of the stem 6 to couple the support frame 3 to the stem 6. Alternatively, the support frame may be soldered, fastened, glued, or otherwise reversibly or irreversibly coupled to the stem. In some embodiments, the shaft 12 of the stem 6 may be configured to receive a delivery catheter, as described below in association with FIG. 10. For example, the shaft 12 may include helical grooves 14 such that a shaft of the delivery catheter may be screwed into the shaft of the stem 6, as shown in FIGS. 2D, 4B, and 4C.



FIGS. 5A and 5B illustrate a top view and side view, respectively, of a membrane 5 coupled to a support frame 3 of a ventricular partitioning device in accordance with a preferred embodiment. The membrane 5 coupled to the support frame 3 is a pressure-receiving surface of the ventricular partitioning device, such that the elastic recoil force of the ventricle is improved when the ventricular partitioning device is implanted. The membrane 5 may be stretched over the struts to give the frame a disk like shape. The membrane 5 may include expanded Polytetrafuoroethylene (ePTFE) having a thickness between 0.01 mm and 1 mm. In one embodiment, the membrane has a thickness of about 0.08 mm. Alternatively, in some embodiments, the membrane 5 may include mesh, or other appropriate permeable, semi-permeable, or impermeable membranes. In some embodiments, the membrane 5 may be formed of a suitable biocompatible polymeric material including Nylon, PET (polyethylene terephthalate) and polyesters such as Hytrel. In some embodiments, the membrane 5 may be porous to facilitate tissue ingrowth after deployment within a patient's heart.


As shown in FIG. 5B, the first free ends 4a of the support frame 3 coupled to the membrane 5 may deflect away from the centerline axis of the ventricular partitioning device when the ventricular partitioning device is deployed in a ventricle. The deflection may improve the anchoring of the ventricular partitioning device to an interior wall of a ventricle.


In some embodiments, as shown in FIGS. 5A, 6A, and 6B, the support frame 3 may, include a plurality of radially expandable struts 4. The struts 4 may be configured to support a membrane 5 coupled to the struts. The struts 4 may improve the elastic recoil properties of the membrane 5 coupled to the struts 4. In some embodiments, the struts 4 may be configured for anchoring the ventricular partitioning device to an interior wall of the ventricle. In some embodiments, the support frame 3 may include 5 struts, 10 struts, 15 struts, or 20 struts. In one embodiment, the support frame 3 includes 16 struts. In some embodiments, each strut 4 may be 1 to 8 cm in length. In one embodiment, each strut 4 has a length of about 3 to 6 cm. In some embodiments, the support frame 3 may be smoothed to a particular surface roughness to reduce trauma to the patient during delivery and improve characteristics of the ventricular partitioning device, such as corrosion resistance and durability. The support frame 3 may be electropolished, chemically treated, and/or mechanically polished by a wheel, tumbling, abrasion, sand blasting, chemical etching, and/or any other method of polishing to achieve a particular surface roughness. In some embodiments, the roughness average (Ra) of the support frame may be between 0.01 μm and 1 μm. In one embodiment, the roughness average (Ra) of the support frame is between about 0.85 μm and 0.15 km.


In some embodiments, as shown in FIGS. 6A-6C, each strut 4 of the support frame 3 may include a first free end 4a and a second end 4b coupled to the foot. The first free end 4a of the support frame 3 may include an anchor or barb 15 for coupling the support frame 3 to an interior wall portion of a heart. This anchoring may allow the ventricular partitioning device to contract and relax with each systolic and diastolic phase, respectively, of the heart cycle. Further, the anchoring may partition the heart into functional and non-functional portions, such that the non-functional portion is proximal to the foot of the ventricular partitioning device.


In some embodiments, as shown in FIGS. 6A-6C, a stop 16 may be located at or near the base of the anchors 15 proximal to the first free end 4a of the struts 4. The stop 16 may be a bulge, projection, or otherwise widening of a portion of the strut 4 near the first free end 4a, which serves to lock the support frame 3 in place and/or reduce or prevent over-penetration of the struts 4 into the ventricle wall. The length of the struts 4 may alternate between a short length strut and a long length strut so that the anchors 15 and/or stops 16 are staggered, which allows the struts 4 to be collapsed into a more compact diameter for delivery.


In some embodiments, as shown in FIG. 6A, each first free end 4a of the strut 4 of the support frame 3 may further include an eyelet 16a. The eyelet 16a may serve as a stop 16, as described above, and/or as a mechanism to couple the membrane to the support frame. During manufacturing, polymer may be melted near the eyelet 16a of the support frame 3 to couple the membrane to the support frame, such that the melted polymer may flow from one side of the strut 4 through the eyelet 16 to the other side of the strut 4 to couple the membrane to the struts 4. As shown in an alternative embodiment in FIGS. 6B-6C, the stop 16, as described above, may be manufactured without an eyelet, such that the polymer melts around the stop 16 and secures the membrane to the support frame 3.


In some embodiments, as shown in FIGS. 7A-7D, the struts may include a material such as, for example, Nitinol, stainless steel, titanium alloys, NiTi alloy, other metal alloys, or plastic composites. In some embodiments, the struts 4 and/or support frame 3 may include a material, which allows for compression of the first free ends towards the central axis during delivery and self expansion upon deployment of the ventricular partitioning device in a patient's heart. In some embodiments, the struts 4 and/or support frame 3 may be cut, for example by a laser, from a tube including Nitinol, stainless steel, or a similar material. During manufacturing, a plurality of longitudinal cuts may extend from one end of the metal tube to a position offset from the other end of the tube, leaving a hub 17 from which the struts 4 extend. The cuts may result in a plurality of slots 18 between the struts 4. In some embodiments, as shown in FIG. 7A, the spacing between the slots 18 may define the strut width W while the thickness of the tube may define the strut thickness T. In some embodiments, the spacing of the slots 18 around the tube may result in struts 4 having a cross-sectional width that is slightly greater than its cross-sectional thickness. This may be accomplished by the slot 18 having a slightly greater spacing than the thickness of the tube. In some embodiments, slightly greater may mean about 1, 2, 3, 4, 5, 10, 15, 20, or 25 percent, or may mean between about 1 to 25 percent, or may mean between about 5 to 20 percent.


In some embodiments, as shown in FIG. 7B, the base 4c of the strut 4 is the second end of the strut that couples to the foot and extends from the hub 17. The base 4c of the strut 4 may be flared such that the width of the strut 4 increases as it approaches the hub 17. In some embodiments, the flared base 4c may spread bending strains over a larger amount of material, thereby decreasing peak strains during manufacturing, loading of the implant within a catheter, and cyclical use in the ventricle after implantation. In some embodiments, the width of the strut 4 at the hub 17 may be about 5 to 25 percent larger than the width of the strut 4 at a middle portion of the strut 4. In some embodiments, the length of the flared base 4c may be about equal to the width of the flared base 4e at the hub 17. Alternatively, the length of the flared base 4c may be greater than about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, or 200 percent of the width of the flared base 4c at the hub 17. Alternatively, the length of the flared base 4c may be less than about 95, 90, 85, 80, 75, 70, 65, 60, 55, or 50 percent of the width of the flared base 4c at the hub 17. The flared base may be formed by tapering the slot as it reaches the hub.


As illustrated in FIG. 7C, in some embodiments, the flared base can have a base bend radius 19 that is sized to (1) reduce or limit peak strains during shape setting to reduce or prevent damage and cracking of the metal frame; (2) reduce or limit peak strains when the implant is loaded into the catheter and reduce or prevent plastic deformation of the metal; and (3) reduce or minimize the height of the implant. In some embodiments, the diameter of the support frame 3 in its free shape 3a can be slightly oversized relative to its laminated shape 3b so that the membrane will stay tight after lamination. For example, the support frame 3 can be oversized by about 3, 4, 5, 6, or 7 mm, or be oversized between about 2 to 10 mm. The lamination mold is designed to conform to the natural shape of the support frame 3 when it is reduced to the lamination diameter 3b. This ensures that the support frame 3 is free to move as designed with little or no alternating strain concentrations.


As shown in FIG. 7D, after lamination, there is a strut curvature 20 near the anchor on the free ends 4a of the struts 4 that is designed to optimize the angle of engagement with the left ventricle wall, which improves retention of the implant in the left ventricle. In some embodiments, the strut curvature 20 has a radius of about 0.5 to 1.5 inches. In some embodiments, the angle of engagement is about 30 to 60 degrees.


In some embodiments as described above, the strut cross-section dimensions having a width slightly greater than the thickness, in conjunction with the flared base, may bias the strut so that it deflects outwardly without any significant twist. This may improve the strength of the struts and reduce strain.


Loading and Delivery Systems


In some embodiments, a delivery system for a ventricular partitioning device may include an implant loading system, which collapses the ventricular partitioning device into a substantially linear delivery configuration for passage into a guide catheter and into a heart, and which expands the ventricular partitioning device into an umbrella-like shape once the device is delivered into a heart. In some embodiments, the ventricular partitioning device may be delivered transapically, percutaneously, endovascularly, or through any other appropriate means or procedure. In some embodiments, the ventricular partitioning device is coupled to a delivery catheter to facilitate loading into the guide catheter. In some embodiments, the ventricular partitioning device is coupled to a shaft disposed in a lumen of the delivery catheter, for example by screwing the ventricular partitioning device to a shaft in a lumen of the delivery catheter, as shown in FIG. 11.


Described below are two different embodiments of an implant loading system for loading a ventricular partitioning device into a guide catheter. The system as shown in FIGS. 8A-9C requires fewer steps and components as compared to the implant loading system described in FIGS. 10A-10D. However, as evident to one of skill in the art, both implant loading systems may be used to load a ventricular partitioning device into a lumen of a guide catheter for delivery to a heart of a patient.


In some embodiments, as shown in FIGS. 8A-9C, an implant loading system for a ventricular partitioning device may include a funnel 21 with a flared first end 21a and a second end 21b, wherein the flared first end 21a is configured for receiving a collapsed ventricular partitioning device 1, as shown in FIGS. 8B and 8D, and a sleeve 22 removably coupled to the second end 21b of the funnel 21, such that the sleeve 22 is configured to transfer the ventricular partitioning device 1 to a guide catheter, as shown in FIGS. 8C and 8D.



FIGS. 8A-8D and 9A-9C illustrate an exterior and cross-sectional view, respectively, of an implant loading system for a ventricular partitioning device, in accordance with a preferred embodiment. As shown in FIGS. 8A-8D, a ventricular partitioning device 1 may be coupled to a delivery catheter 23, as described below. The ventricular partitioning device 1 may be collapsed by drawing at least two sutures, strings, ties, or threads together, such that the diameter of the membrane and thus the ventricular partitioning device is reduced. In this manner, the ventricular partitioning device 1 may be at least partially collapsed around the delivery catheter 23. As used herein, “two sutures, strings, ties, or threads” may refer to two separate sutures, strings, ties, or threads, or two separate ends of a looped suture, string, tie, or thread. In some embodiments, the at least two sutures may be coupled by a tab, such that both sutures may be tensioned and the ventricular partitioning device at least partially collapsed by manipulating the tab.


In some embodiments, the ventricular partitioning device may be positioned in the flared first end 21a of the funnel 21 with the first free ends of the struts of the ventricular partitioning device entering the flared first end 21a of the funnel 21 followed by the foot 2 of the ventricular partitioning device, as shown in FIG. 8D. The funnel 21 may function to fully collapse the ventricular partitioning device for advancement into a lumen of a guide catheter. In some embodiments, as shown in FIG. 8A, the second end 21b of the funnel 21 is removably coupled to a second, distal end 22b of a sleeve 22, for example by threading 33 the funnel 21 onto the second, distal end 22b of the sleeve 22, as shown in FIGS. 8A and 8C. One embodiment of the threads 33 for coupling the funnel 21 to the sleeve 22, as shown in FIG. 9B, is evident using a cross-sectional view of the funnel 21 and sleeve 22, such as shown in FIGS. 9A and 9C. Alternatively, the funnel 21 may be coupled to the sleeve 22 by any suitable mechanism. In some embodiments, the ventricular partitioning device coupled to the delivery catheter 23 may be advanced through the funnel 21 into the sleeve 22 for loading of the ventricular partitioning device into a lumen of a guide catheter. The first, proximal end 22a of the sleeve 22 may include a stop or tapering of the sleeve, such that the ventricular partitioning device does not protrude from the first, proximal end 22a of the sleeve 22 or extend out of the first end 22a of the sleeve 22, as shown in FIGS. 8A-8C. In some embodiments, the interior of the funnel 21 and sleeve 22 may include a smooth surface, for example without flashes or burrs, such that the ventricular partitioning device is not torn or scratched during loading, unloading, and advancing. Once, the ventricular partitioning device is advanced into the sleeve 22 from the funnel 21, the funnel 21 may be uncoupled from the second, distal end 22b of the sleeve 22 and the guide catheter may be coupled in its place.


Further, as shown in FIG. 14, in some embodiments, the sleeve 22 may include a fluid delivery port 122, such that fluid, for example saline, may be injected into the sleeve, as described in further detail below. In some embodiments, the fluid is substantially prevented or inhibited from exiting the first or proximal end of the sleeve by a mechanical seal 123 coupled to the first or proximal end 22a of the sleeve 22. The mechanical seal 123 may be, for example, a gasket, O-ring, bung comprising an aperture, bodok seal, hermetic seal, diaphragm seal, labyrinth seal, rotating hemostatic valve, or any other suitable sealing mechanism. For example, as shown in FIG. 12F, the mechanical seal 80 may be a rotating hemostatic valve, which can be rotated to adjust the size of the valve aperture to maintain hemostasis while allowing passage of the delivery catheter and implant through the valve and into the sleeve 22 and guide catheter. In various embodiments, the mechanical seal 123 is sized to contact an inner surface of the sleeve and an outer surface of the delivery catheter 23 to form a liquid-tight or fluid-tight seal. Alternatively, the mechanical seal may be positioned and formed so as to create a liquid-tight or fluid-tight seal by any mechanism known to one skilled in the art. The mechanical seal 123 may be adhered, fastened, or otherwise coupled to the sleeve 22 using any suitable attachment mechanism. Alternatively, the mechanical seal may be integrally molded or otherwise formed with the sleeve.


In some embodiments, for example as shown in FIGS. 15A and 15B, the distal end 22b of the sleeve 22 may be coupled to a guide catheter 51. In some embodiments, the distal end 22b of the sleeve 22 may be coupled to a guide catheter 51 using a valve 84, such as a hemostatic valve. The valve 84 may be positioned in the sleeve 22, in the guide catheter 51, or in a separate joint coupling the sleeve 22 to the guide catheter 51, for example a joint (e.g., T-port) comprising a fluid delivery port 57. In some embodiments, the valve 84 may be a rotating valve, which is configured to rotate to increase or decrease the size of the aperture in the valve 84 to allow the passage of the delivery catheter 23 and implant 1 or other medical device through the valve 84 while maintaining a fluid-tight seal around the delivery catheter 23. In some embodiments, the guide catheter 51 can also include a fluid delivery port 57 for introducing fluid into guide catheter.


Additionally or alternatively, in some embodiments, as shown in FIGS. 15A and 15B, the coupling between the guide catheter 51 and the sleeve 22 further includes a second hemostatic valve, such as a check valve or duck-bill valve 85, to reduce or prevent backflow before the delivery catheter 23 is inserted into the guide catheter 51 and the valve is empty. In some embodiments, the check valve or duck-bill valve 85 forms a portion of the guide catheter 51; in other embodiments, the check valve or duck-bill valve 85 forms a portion of a separate joint (e.g., T-port) coupling the sleeve 22 to the guide catheter 51. In some embodiments, the check valve or duck-bill valve 85 covers or seals a proximal end 54 of the guide catheter 51. In one such embodiment, one end of the valve stretches over the proximal end 54 of the guide catheter 51, conforming to its shape, and a second end extends distally into the guide catheter 51. In some such embodiments, a first flap or side 86a and a second flap or side 86b of the check valve or duck-bill valve 85 form complementary surfaces that interlace or interweave when a delivery catheter is not present, as shown in FIG. 15A, and are displaced or splayed open when a delivery catheter is present, as shown in FIG. 15B. In some embodiments, the check valve or duck-bill valve comprises elastic or stretchable material, such that it conforms to the surface of the device or catheter extending through the valve. In some such embodiments, the check valve or duck-bill valve comprises rubber or synthetic elastomer.


The ventricular partitioning device may be advanced from the sleeve into the lumen of the guide catheter. In some embodiments, the delivery catheter 23 coupled to the ventricular partitioning device may be advanced through the guide catheter lumen into a heart of a patient to position the ventricular partitioning device in the heart of the patient. In some embodiments, the sleeve may be removed from the delivery catheter by any suitable mechanism after advancing the ventricular partitioning device into the lumen of the guide catheter. Alternatively, the delivery catheter may be lengthened such that the sleeve may remain on the delivery catheter while the ventricular partitioning device is being positioned in a heart of a patient.


Alternatively, in some embodiments as shown in FIGS. 10A-10D, an implant loading system for a ventricular partitioning device may further include a loader 24 comprising a lumen housing a two-piece introducer 25, referred to herein as a loader introducer pair. Instead of a two-step loading procedure, as shown in FIGS. 8A-9C, the loading procedure shown in FIGS. 10A-10D includes at least two more steps. In some embodiments, as show in FIG. 10A, the funnel 26 for loading the ventricular partitioning device into the sleeve 27 may be truncated as compared to the funnel 21 shown in FIG. 8B. Similar to FIGS. 8A and 8D, the tapered end 26b of the funnel 26 may be coupled to the second end 27b of the sleeve 27 and the ventricular partitioning device coupled to the delivery catheter may be advanced from the funnel 26 into the sleeve 27. In some embodiments, as shown in FIG. 10C, once the ventricular partitioning device is collapsed and advanced through the funnel 26 into the sleeve 27, the funnel 26 may be uncoupled from the second end 27b of the sleeve 27 and the second end 24b of the loader introducer pair 24/25 may be coupled to the second end 27b of the sleeve 27. The loader introducer pair 24/25 may be coupled to the sleeve 27 by a helical screw, latching, snapping, fastening, or any other type of coupling mechanism. The first end 24a of the loader introducer pair 24/25 may be coupled to a guide catheter, such that the lumen of the loader introducer pair is continuous with the lumen of the guide catheter. In some embodiments, as shown in FIG. 10C, the coupling mechanism may include a slot 28 on the loader 24 and a pin, knob, protrusion, or port on the guide catheter, such that the slot 28 receives the pin or port and secures the loader 24 to the guide catheter. Alternatively, the loader 24 may be coupled to the guide catheter by a helical screw, snapping, latching, or any other type of coupling mechanism.


As shown in FIG. 10C, the ventricular partitioning device may be advanced from the sleeve 27 into the loader introducer pair 24/25 and into the guide catheter. The loader 24 may be removed from the system by moving the introducer 25 and delivery catheter through a longitudinal slot 29 in the loader 24. The introducer 25 may be removed from the system by, tearing or axially pulling apart the two halves 25a/25b of the introducer 25, as shown in FIG. 10D, such that the delivery catheter coupled to the ventricular partitioning device in the lumen of the guide catheter remains. In some embodiments, the sleeve 27 may remain on the delivery catheter or be removed. While two embodiments of an implant loading system are described above, any other suitable mechanism may be used and/or substituted by one skilled in the art to deliver a ventricular partitioning device to a heart of a patient.


In some embodiments, as shown in FIG. 11, a system for treating heart failure may include a ventricular partitioning device as described above, and a delivery catheter 23 having a proximal end and a distal end 23b. Further, a system for treating heart failure may include an expansion member 30 near the distal end 23b of the delivery catheter 23 configured to apply pressure to the support frame 3 of the ventricular partitioning device 1 to move the ventricular partitioning device 1 from a collapsed delivery configuration to an expanded deployed configuration, and a coupling element 31 configured to secure the expansion member 30 to the ventricular partitioning device 1 during deployment.


In some embodiments, the expansion member 30 is coupled to the ventricular partitioning device 1 by a coupling element 31 proximal to the second ends 4b of the struts 4 of the support frame 3. In some embodiments, the coupling element 31 includes a helical screw, as shown in FIG. 11. Alternatively, in some embodiments, the coupling element 31 may include a sliding latch, lock, hook, or any other suitable mechanism. In some embodiments, the expansion member 30, for example a balloon, may be in fluid communication with a lumen in the shaft of the delivery catheter 23, such that inflation fluid may be delivered to the interior of the expansion member 30 to inflate the balloon. Alternatively, the balloon may be inflated by a gas, gel, or any other material. The balloon, once inflated, may include a diameter between 30 mm and 45 mm. In one embodiment, the balloon, once inflated, has a diameter of more than or equal to 32 mm.


In some embodiments, the ventricular partitioning device 1 radially expands in the ventricle once delivered to the ventricle. The expansion member 30, coupled to the ventricular partitioning device 1 by a coupling element 31, may be inflated at the distal end of the delivery catheter 23 to fully expand the ventricular partitioning device 1 within the ventricle and to facilitate anchoring the struts 4 of the ventricular partitioning device to an interior wall of the ventricle. Alternatively, in some embodiments, the ventricular partitioning device 1 may expand and anchor sufficiently without the use of the expansion member 30. In some embodiments, rotation of the delivery catheter 23 coupled to the ventricular partitioning device 1 may remove the expansion member 30 and delivery catheter 23 from the ventricular partitioning device 1.


In some embodiments, a delivery system for an implantable ventricular partitioning device includes a delivery catheter, a sleeve, a first fluid delivery port, and a guide catheter. Such devices may include any or all of the features described in the embodiments provided above. In some embodiments, such as shown in FIGS. 12-13, the delivery catheter 52 is formed of a tubular body, or shaft, includes a proximal end and a distal end, and is configured to couple to a ventricular partitioning device or other implantable device. The implant loader sleeve 22 of various embodiments defines a lumen configured to receive the delivery catheter 52 and the implantable device, as previously described above. In some embodiments, the first fluid delivery, port 61 is positioned on the delivery catheter 52, as illustrated in FIG. 12A, and/or a fluid deliver port can be located on the sleeve 22, as shown in FIG. 14, and a mechanical seal 42 is coupled to the sleeve 22. For example, the mechanical seal 42 can be a gasket or other sealing device, as further described herein, that is located in the proximal end of the sleeve 22. The mechanical seal 42 of some embodiments is sized to contact an inner surface of the sleeve 22 and an outer surface of the delivery catheter 52 to form a liquid-tight seal. In some embodiments, the guide catheter 51 is formed of a tubular body having a proximal end, a distal end, a lumen extending therethrough for receiving the delivery catheter 52, and a second fluid delivery port 57 positioned thereon. In various embodiments, the proximal end of the guide catheter 51 is connected to the distal end of the sleeve 22. In some embodiments, the fluid delivery ports can be opened and closed by, for example, using a valve or by clamping the lines supplying fluid to the ports.


The system, as shown in FIGS. 12-13, functions to maintain the implantable device (e.g. ventricular partitioning device) relatively free of blood during implantation, reduce or prevent the flow of blood back into the delivery system during implantation of the ventricular partitioning device, reduce friction between the ventricular partitioning device and the delivery, system, and/or facilitate easy opening of the ventricular partitioning device in the ventricle.


In some embodiments, delivering fluid through the first and/or second fluid delivery ports, for example at a positive pressure, creates a first pressure in the guide catheter that is greater than a second pressure in the ventricle. Such fluid delivery is shown with two fluid delivery arrows in FIG. 12B. The resulting increased pressure in the guide catheter may reduce or prevent blood from flowing backward into the guide catheter and onto the ventricular partitioning device. It has been found that in at least some embodiments, deployment of the device in the ventricle is achieved more easily with more consistent and effective results when it does not get loaded down with blood during the implantation process.


In some embodiments, the positive pressure of fluid delivery is about 150-200, 200-250, 250-300 mm Hg, or any other suitable pressure. In some embodiments, the first pressure is between 200 and 600 mm Hg, and preferably 200-400 mm Hg, and the second pressure is between 0 and 300 mm Hg, and preferably 75-175 mm Hg. In some embodiments, the first pressure is about 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-550, or 550-600 mm Hg, and the second pressure is about 5-100, 100-150, 150-200, 200-250, or 250-300 mm Hg. In one embodiment, the first pressure is about 300 mm Hg and the second pressure is about 120 mm Hg. In some embodiments, the fluid can be delivered at a positive pressure using a pressurized fluid reservoir, such as a pressurized IV bag, for example.


Alternatively, in some embodiments, the fluid can be delivered at a predetermined rate using a pump. The flow rate of fluid through the catheter can be about 30-120 mL/min, or about 0.5-5 mL/sec, or about 0.5, 1.0, 1.5, or 2.0 mL/sec. In some embodiments, the flow rate can be adjusted by the operator.


In some embodiments, the injection of fluid through the first and/or second fluid delivery ports may alternatively or additionally function to remove bubbles from the delivery system. For example, the first fluid delivery port of the delivery catheter can be used to introduce fluid while the second fluid delivery port, which can be located on the guide catheter, can be used to aspirate any trapped gas bubbles. Generally, the bubbles can be aspirated using a fluid delivery port that is distal to the implant. Alternatively, the delivery system as described may be used in any suitable catheterization and/or implantation procedure or method.


As shown in FIGS. 12A and 13, the delivery catheter 52 includes a proximal end 40 and a distal end 41. The distal end 41 of the delivery catheter 52 is configured to couple to an implantable device, for example a ventricular partitioning device, as described above. In some embodiments, the delivery catheter 52 has an outer shaft 58 with an interior (i.e., lumen) 59, and an adapter 60 at a proximal end with a first fluid delivery port 61. The first fluid delivery port 61 is in fluid communication with the interior 59 of the outer shaft 58 of the delivery catheter for delivery of fluid, for example heparinized saline, into the delivery system. Alternatively, in some embodiments, the first fluid delivery port may be positioned on the sleeve configured to receive the implantable device coupled to the delivery catheter, as described above in FIG. 14.


Further, the delivery catheter 52 may include a torque shaft 67. The torque shaft 67, preferably formed from hypotubing (e.g., stainless steel or superelastic NiTi) and having an inner lumen 68, is rotatable and disposed within an inner lumen 69 of the inner shaft 62 of the delivery catheter 52. The torque shaft 67 may be secured at a proximal end 70 of the delivery catheter 52 within an adapter 71 with a rotating knob 72. In some such embodiments, an inflation port 73, proximal to the rotating knob 72, is in fluid communication with the inner lumen 68 of the torque shaft 67. A coupling element 74, for example a helical coil screw, is secured to a distal end 75 of the torque shaft 67. Rotation of the torque knob 72 on the proximal end 70 of the torque shaft 67 rotates the coupling element 74 on the distal end 75 of the torque shaft 67 to facilitate deployment of the implantable device 30. An expansion member 76, for example an inflatable balloon, is secured at its proximal end 77 to the torque shaft 67 at a location proximal to the distal end 75 of the torque shaft 67. In some embodiments, the expansion member 76 is secured to the torque shaft 67 by an adhesive or other fastening mechanism in a manner that creates a fluid-tight seal. The expansion member 76 has an interior 79 in fluid communication with the inner lumen 68 of the torque shaft 67. Inflation fluid may be delivered to the interior 79 of the expansion member 76 through the port 73. Inflation of the expansion member 76 by delivering inflation fluid through the port 73 facilitates opening of the implantable device in the ventricle, which in turn facilitates securement of the implantable device 30 to the heart wall.


In some embodiments, the mechanical seal 42, as shown in FIGS. 12B-12E, functions to create a liquid-tight or fluid-tight seal between the sleeve 22 and the delivery catheter 52, such that there is reduced loss of liquids from the delivery system. FIG. 12B illustrates the sleeve 22 attached to the guide catheter 51 and the delivery catheter 52 inserted into and through the sleeve 22. FIG. 12C illustrates a front view of an embodiment of the mechanical seal 42 with an opening for removably receiving the delivery catheter 51. FIG. 12D is a cross-sectional view and FIG. 12E is a side view of an embodiment of the sleeve with a mechanical seal 42. The mechanical seal 42 is coupleable to the sleeve 22. In some embodiments, the mechanical seal 42 is sized and positioned to contact an inner surface of the sleeve 22 and an outer surface of the outer shaft 58 of the delivery catheter 52 while the implantable device coupled to the delivery catheter is positioned in the sleeve 22. The mechanical seal may include a gasket, O-ring, bung including an aperture, bodok seal, hermetic seal, diaphragm seal, labyrinth seal, or any other type of seal known to one of skill in the art. The mechanical seal 42 can be located at the proximal end of the sleeve 22. The mechanical seal 42 can be elastic or partially elastic, such as around the opening of the seal, in order to conform to and form a fluid tight seal around the delivery, catheter 52.


In some embodiments, as shown in FIGS. 12B-13, the guide catheter 51 functions to receive a ventricular partitioning device from the sleeve 22 and position the ventricular partitioning device in a ventricle. The guide catheter 51 includes a tubular body defining an inner lumen 53 extending between a proximal end 54 and a distal end 55. The proximal end 54 of the guide catheter 51 is coupled to the distal end 44 of the sleeve 22, for example through a connector, a hemostatic valve 43, or any other type of valve. In some embodiments, the guide catheter 51 further includes a second fluid delivery port 57 on the proximal end 54 of the guide catheter 51. The second fluid delivery port 57 is configured for injecting fluids, for example heparinized saline, through the guide catheter. The second fluid delivery port 57 is in fluid communication with the inner lumen 53 of the guide catheter 51.


Methods


As shown in FIG. 16 a method of preparing a ventricular partitioning device for implantation using a delivery system includes: coupling the ventricular partitioning device to a delivery catheter S100; loading the ventricular partitioning device and a portion of the delivery catheter into a sleeve and creating a liquid-tight seal between a portion of the sleeve and the delivery catheter S110; coupling a distal end of the sleeve to a guide catheter S120; and delivering fluid through a first fluid delivery port disposed on the delivery catheter or the sleeve and/or delivering fluid through a second fluid delivery port disposed on the guide catheter S130. In various embodiments, delivering the fluid creates a first pressure in the guide catheter that is greater than a second pressure in a ventricle. The method of FIG. 16 functions to maintain the ventricular partitioning device relatively free of blood during implantation, reduce or prevent the flow of blood back into the delivery system during implantation of the ventricular partitioning device, reduce friction between the ventricular partitioning device and the delivery system, and facilitate easy opening of the ventricular partitioning device in the ventricle. Alternatively, the methods described may be used in any suitable catheterization and/or implantation procedure or method.


As shown in FIG. 16, one embodiment of preparing a ventricular partitioning device for implantation using a delivery system includes block S100, which recites coupling the ventricular partitioning device to a delivery catheter. S100 functions to attach, screw, adhere, or otherwise fasten the ventricular partitioning device to the delivery catheter. As described above, in one embodiment, the delivery catheter may include a helical screw at the distal tip configured for mating with threads in the stem of the ventricular partitioning device. Alternatively, any other coupling mechanism may be utilized.


As shown in FIG. 16, one embodiment of preparing a ventricular partitioning device for implantation using a delivery system includes block S110, which recites loading the ventricular partitioning device and a portion of the delivery catheter into a sleeve and creating a liquid-tight or fluid-tight seal between a portion of the sleeve and the delivery catheter. In the loaded configuration, the ventricular partitioning device is positioned in the sleeve and the delivery catheter extends out of the first or proximal end of the sleeve. A mechanical seal coupled to the proximal end of the sleeve may create the liquid-tight or fluid-tight seal between the sleeve and the delivery catheter, such that any liquid or fluid injected into the delivery system is substantially maintained in the delivery system. In various embodiments, the delivery catheter or the sleeve includes a first fluid delivery port positioned thereon. S110 functions to prepare a ventricular partitioning device for implantation, for example by collapsing the ventricular partitioning device using the sleeve and positioning the ventricular partitioning device for transfer into a guide catheter. As described above, a funnel may be coupled to the sleeve to facilitate loading of the ventricular partitioning device into the sleeve. In some such embodiments, the ventricular partitioning device coupled to the delivery catheter may be loaded first free ends first into the flared end of the funnel and advanced from the funnel into the sleeve. The funnel may be removed from the sleeve, and as described below, a guide catheter may be coupled in its place at the distal end of the sleeve.


As shown in FIG. 16, one embodiment of preparing a ventricular partitioning device for implantation using a delivery system includes block S120, which recites coupling a distal end of the sleeve to a guide catheter. S120 functions to prepare the ventricular partitioning device for advancement from the sleeve to the guide catheter for delivery into a ventricle. The sleeve of some embodiments is coupled to a valve, such as a hemostatic valve, on the proximal end of the guide catheter. The guide catheter of some embodiments has a second fluid delivery port positioned thereon. In some embodiments, the method includes advancing the ventricular partitioning device coupled to the delivery catheter through one or more valves (e.g., hemostatic valve, check valve, duck-bill valve, etc.) on the proximal end of the guide catheter into the tubular body of the guide catheter.


A s shown in FIG. 16, one embodiment of preparing a ventricular partitioning device for implantation using a delivery system includes block S130, which recites delivering fluid through at least one of the first fluid delivery port or the second fluid delivery port, such that delivering the fluid creates a first pressure in the guide catheter that is greater than a second pressure in a ventricle. S130 functions to reduce or prevent blood backflow into the delivery system during implantation of the ventricular partitioning device. Further, flushing the delivery system with saline reduces blood accumulation on the ventricular partitioning device resulting in improved expansion of the ventricular partitioning device upon implantation in the ventricle. In some embodiments, the first pressure is between 200 and 600 mm Hg, and preferably 200-400 mm Hg, and the second pressure is between 0 and 300 mm Hg, and preferably 75-175 mm Hg. The first pressure created in the guide catheter of other embodiments is about 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-550, or 550-600 mm Hg. In one embodiment, the first pressure is about 300 mm Hg. The second pressure in the ventricle of some embodiments is about 5-100, 100-150, 150-200, 200-250, or 250-300 mm Hg. In one embodiment, the second pressure is about 120 mm Hg. In some embodiments, the fluid, for example heparinized saline, is delivered at a positive pressure into the first and/or second fluid delivery ports, such that the pressure in the guide catheter prevents or substantially prevents blood from flowing backwards into the guide catheter, while continued distal movement of the delivery catheter through the guide catheter pushes the ventricular partitioning device out of the guide catheter and into the ventricle. Alternatively, the first and/or second fluid delivery ports may be utilized to remove bubbles from the delivery system, for example, by opening the fluid delivery ports to the atmosphere.


In some embodiments, a method of preparing a ventricular partitioning device for implantation further includes: transferring the ventricular partitioning device from the sleeve to the guide catheter; positioning with a delivery catheter a ventricular partitioning device near an apex of a patient's ventricle; delivering the ventricular partitioning device from the guide catheter into the ventricle; expanding an expansion member coupled to the partitioning device to apply pressure to the plurality of expandable struts to expand the partitioning device; and uncoupling the delivery catheter from the ventricular partitioning device, as described above. In some embodiments, a method of delivering a ventricular partitioning device may further include positioning a delivery sheath over the partitioning device to collapse the partitioning device for removal or redeployment of the partitioning device.


In some embodiments, a method of preparing a ventricular partitioning device for implantation further includes allowing blood from the patient's body to enter the guide catheter through the distal end of the guide catheter and exit the guide catheter through the second fluid delivery port disposed on the guide catheter. This step may occur prior to and/or as the ventricular partitioning device is advanced from the sleeve into the guide catheter. Allowing the backflow of blood into the guide catheter and out the second fluid delivery port removes any air that may be present between the second fluid delivery port and the ventricular partitioning device as the ventricular partitioning device is advanced into the guide catheter.


Further, in some embodiments, delivering fluid through at least one of the first fluid delivery port or the second fluid delivery port includes pushing or otherwise introducing fluid, for example saline, into the guide catheter using the first fluid delivery port disposed on the delivery catheter or the sleeve. In some such embodiments, the fluid is substantially maintained in the guide catheter by the fluid-tight or liquid-tight seal, for example the seal established by the mechanical seal. This fills the space behind the ventricular partitioning device with saline as the ventricular partitioning device is advanced, preventing air from being drawn into the guide catheter.


In some embodiments, a method of preparing a ventricular partitioning device for implantation further includes closing, sealing, or otherwise blocking the second fluid delivery port disposed on the guide catheter after the ventricular partitioning device is advanced distally beyond the second fluid delivery port of the guide catheter. This may ensure, for example, that the saline or other fluid delivered via positive pressure through the first fluid delivery port is not expelled through the second delivery port but rather advances through the guide catheter.


As used in the description and claims, the singular form “a”, “an” and “the” include both singular and plural references unless the context clearly dictates otherwise. For example, the term “a fluid delivery port” may include, and is contemplated to include, a plurality of fluid delivery ports. At times, the claims and disclosure may include terms such as “a plurality,” “one or more,” or “at least one;” however, the absence of such terms is not intended to mean, and should not be interpreted to mean, that a plurality is not conceived.


The term “about” or “approximately,” when used before a numerical designation or range (e.g., to define a length or pressure), indicates approximations which may vary by (+) or (−) 5%, 1% or 0.1%. All numerical ranges provided herein are inclusive of the stated start and end numbers. The term “substantially” indicates mostly (i.e., greater than 50%) or essentially all of a device, substance, or composition.


As used herein, the term “comprising” or “comprises” is intended to mean that the devices, systems, and methods include the recited elements, and may additionally include any other elements. “Consisting essentially of” shall mean that the devices, systems, and methods include the recited elements and exclude other elements of essential significance to the combination for the stated purpose. Thus, a device or method consisting essentially of the elements as defined herein would not exclude other materials, features, or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention. “Consisting of” shall mean that the devices, systems, and methods include the recited elements and exclude anything more than a trivial or inconsequential element or step. Embodiments defined by each of these transitional terms are within the scope of this disclosure.


The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. Other embodiments may be utilized and derived therefrom, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is in fact disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.

Claims
  • 1. A delivery system for an implantable device, the system comprising: a delivery catheter comprising a tubular body having a proximal end and a distal end and an interior lumen, wherein the delivery catheter is configured to couple to the implantable device;a sleeve defining a lumen configured to receive the delivery catheter and the implantable device coupled thereto;a first fluid delivery port positioned on the delivery catheter and in fluid communication with the interior lumen of the delivery catheter; anda guide catheter comprising a tubular body having a proximal end configured to connect to the sleeve and for the delivery catheter to be inserted into from the sleeve, a distal end, an interior lumen configured to receive the delivery catheter, and a second fluid delivery port positioned on the guide catheter and in fluid communication with the interior lumen of the guide catheter and configured to be in fluid communication with the interior lumen of the delivery catheter and the first fluid delivery port when the delivery catheter is positioned within the interior lumen of the guide catheter, andwherein the second fluid delivery port is configured to aspirate gas from the interior lumen of the guide catheter while fluid is delivered through the first fluid delivery port, or the first fluid delivery port is configured to aspirate gas from the interior lumen of the delivery catheter while fluid is delivered through the second fluid delivery port.
  • 2. The system of claim 1, further comprising a pressurized fluid reservoir configured to be in fluid communication with the delivery catheter.
  • 3. The system of claim 1, further comprising a pump configured to deliver fluid through the delivery catheter.
  • 4. The system of claim 1, further comprising the implantable device, and wherein the implantable device is an expandable device having a support frame.
  • 5. The system of claim 1, wherein the first fluid delivery port and/or the second fluid delivery port are configured to deliver fluid creating a first pressure in the guide catheter of about 200-600 mm Hg.
  • 6. The system of claim 1, wherein the guide catheter further comprises a hemostatic valve positioned at the proximal end of the guide catheter.
  • 7. The system of claim 1, wherein the first fluid delivery port and/or the second fluid delivery port are configured to deliver fluid creating a positive pressure in the guide catheter.
  • 8. The system of claim 1, further comprising a funnel, wherein the funnel comprises a flared first end and a second end, wherein the flared first end is configured for receiving and collapsing the implantable device, and wherein the second end is coupleable to the sleeve.
  • 9. The system of claim 8, wherein the second end of the funnel is configured to be removed from a distal end of the sleeve prior to the distal end of the sleeve connecting to the proximal end of the guide catheter.
  • 10. The system of claim 1, further comprising a first valve positioned at the proximal end of the guide catheter and configured for the delivery catheter to pass through.
  • 11. The system of claim 10, wherein the first valve is a rotating valve.
  • 12. The system of claim 10, wherein the first valve is configured to connect the proximal end of the guide catheter to a distal end of the sleeve.
  • 13. The system of claim 10, further comprising a second valve positioned at the proximal end of the guide catheter and configured for the delivery catheter to pass through.
  • 14. The system of claim 13, wherein the second valve is configured to reduce fluid backflow before the delivery catheter is inserted into the proximal end of the guide catheter.
  • 15. The system of claim 14, wherein the guide catheter includes a T-port, and the first valve, the second valve, and the second fluid delivery port are each positioned on the T-port.
  • 16. The system of claim 1, further comprising a third fluid delivery port positioned on the sleeve and in fluid communication with the lumen of the sleeve.
  • 17. The system of claim 16, wherein the third fluid delivery port is configured to be in fluid communication with the interior lumen of the guide catheter and the second fluid delivery port when the sleeve is connected to the guide catheter.
  • 18. The system of claim 17, wherein the third fluid delivery port is configured to be in fluid communication with the interior lumen of the delivery catheter when the sleeve is connected to the guide catheter and the delivery catheter is positioned within the lumen of the sleeve and the interior lumen of the guide catheter.
  • 19. The system of claim 1, wherein the first fluid delivery port is configured to introduce fluid into the interior lumen of the guide catheter when the delivery catheter is positioned within the interior lumen of the guide catheter.
  • 20. The system of claim 1, wherein the sleeve includes a proximal end and a distal end, the proximal end of the sleeve configured for the delivery catheter to be inserted into, and the distal end of the sleeve is configured to be connected to the proximal end of the guide catheter.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/997,793, filed Aug. 19, 2020, which is a divisional application of U.S. patent application Ser. No. 15/559,680, filed Sep. 19, 2017, now U.S. Pat. No. 10,751,064, which was the National Stage of International Patent Application No. PCT/US2016/022863, filed Mar. 17, 2016, which claims the benefit of U.S. Provisional Application No. 62/136,248, filed Mar. 20, 2015, and titled “SYSTEMS AND METHODS FOR DELIVERING AN IMPLANTABLE DEVICE”, the entire contents of each of which are herein incorporated by reference in their entireties.

US Referenced Citations (697)
Number Name Date Kind
3409013 Berry Nov 1968 A
3472230 Fogarty Oct 1969 A
3548417 Kischer et al. Dec 1970 A
3587115 Shiley Jun 1971 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3739402 Cooley et al. Jun 1973 A
3755823 Hancock Sep 1973 A
4011947 Sawyer Mar 1977 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4079468 Liotta et al. Mar 1978 A
4106129 Carpentier et al. Aug 1978 A
4204283 Bellhouse et al. May 1980 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos et al. May 1981 A
4297749 Davis et al. Nov 1981 A
4339831 Johnson Jul 1982 A
4340977 Brownlee et al. Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4373216 Klawitter Feb 1983 A
4406022 Roy Sep 1983 A
4470157 Love Sep 1984 A
4477930 Totten et al. Oct 1984 A
4490859 Black et al. Jan 1985 A
4535483 Klawitter et al. Aug 1985 A
4553545 Maass et al. Nov 1985 A
4574803 Storz Mar 1986 A
4592340 Boyles Jun 1986 A
4605407 Black et al. Aug 1986 A
4612011 Kautzky Sep 1986 A
4643732 Pietsch et al. Feb 1987 A
4655771 Wallsten Apr 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4733665 Palmaz Mar 1988 A
4759758 Gabbay Jul 1988 A
4762128 Rosenbluth Aug 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4829990 Thuroff et al. May 1989 A
4851001 Taheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4865600 Carpentier et al. Sep 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4922905 Strecker May 1990 A
4966604 Reiss Oct 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5059177 Towne et al. Oct 1991 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5108370 Walinsky Apr 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5192297 Hull Mar 1993 A
5232446 Arney Aug 1993 A
5266073 Wall Nov 1993 A
5282847 Trescony et al. Feb 1994 A
5295958 Shturman Mar 1994 A
5326371 Love et al. Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5360444 Kusuhara Nov 1994 A
5370685 Stevens Dec 1994 A
5397351 Pavcnik et al. Mar 1995 A
5411055 Kane May 1995 A
5411522 Trott May 1995 A
5411552 Andersen et al. May 1995 A
5415667 Frater May 1995 A
5443446 Shturman Aug 1995 A
5480424 Cox Jan 1996 A
5500014 Quijano et al. Mar 1996 A
5545209 Roberts et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554185 Block et al. Sep 1996 A
5571175 Vanney et al. Nov 1996 A
5591185 Kilmer et al. Jan 1997 A
5599305 Hermann et al. Feb 1997 A
5607464 Trescony et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5639274 Fischell et al. Jun 1997 A
5665115 Cragg Sep 1997 A
5697382 Love et al. Dec 1997 A
5716417 Girard et al. Feb 1998 A
5728068 Leone et al. Mar 1998 A
5749890 Shaknovich May 1998 A
5756476 Epstein et al. May 1998 A
5769812 Stevens et al. Jun 1998 A
5800508 Goicoechea et al. Sep 1998 A
5840081 Andersen et al. Nov 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5906619 Olson et al. May 1999 A
5925063 Khosravi Jul 1999 A
5957949 Leonhardt et al. Sep 1999 A
5968068 Dehdashtian et al. Oct 1999 A
6027525 Suh et al. Feb 2000 A
6042607 Williamson et al. Mar 2000 A
6086612 Jansen Jul 2000 A
6113631 Jansen Sep 2000 A
6132473 Williams et al. Oct 2000 A
6168614 Andersen et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6174327 Mertens et al. Jan 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6217585 Houser et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6231602 Carpentier et al. May 2001 B1
6245040 Inderbitzen et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6251093 Valley et al. Jun 2001 B1
6287339 Vazquez et al. Sep 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6306141 Jervis Oct 2001 B1
6312465 Griffin et al. Nov 2001 B1
6350277 Kocur Feb 2002 B1
6358277 Duran Mar 2002 B1
6379372 Dehdashtian et al. Apr 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6482228 Norred Nov 2002 B1
6488704 Connelly et al. Dec 2002 B1
6527800 McGuckin et al. Mar 2003 B1
6527979 Constantz et al. Mar 2003 B2
6540782 Snyders Apr 2003 B1
6569196 Vesely May 2003 B1
6575959 Sarge et al. Jun 2003 B1
6582462 Andersen et al. Jun 2003 B1
6605112 Moll et al. Aug 2003 B1
6610088 Gabbay Aug 2003 B1
6629534 St. Goar et al. Oct 2003 B1
6676698 McGuckin et al. Jan 2004 B2
6695878 McGuckin et al. Feb 2004 B2
6712836 Berg et al. Mar 2004 B1
6716207 Farnholtz Apr 2004 B2
6729356 Baker et al. May 2004 B1
6730118 Spenser et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6746422 Noriega et al. Jun 2004 B1
6749560 Konstorum et al. Jun 2004 B1
6767362 Schreck Jul 2004 B2
6780200 Jansen Aug 2004 B2
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6830584 Seguin Dec 2004 B1
6875231 Anduiza et al. Apr 2005 B2
6893460 Spenser et al. May 2005 B2
6908481 Cribier Jun 2005 B2
6974476 McGuckin et al. Dec 2005 B2
7018406 Seguin et al. Mar 2006 B2
7186265 Sharkawy et al. Mar 2007 B2
7192440 Andreas et al. Mar 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7276078 Spenser et al. Oct 2007 B2
7276084 Yang et al. Oct 2007 B2
7318278 Zhang et al. Jan 2008 B2
7374571 Pease et al. May 2008 B2
7381210 Zarbatany et al. Jun 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7393360 Spenser et al. Jul 2008 B2
7429269 Schwammenthal et al. Sep 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7462191 Spenser et al. Dec 2008 B2
7510575 Spenser et al. Mar 2009 B2
7524330 Berreklouw Apr 2009 B2
7530253 Spenser et al. May 2009 B2
7553324 Andreas et al. Jun 2009 B2
7579381 Dove Aug 2009 B2
7585321 Cribier Sep 2009 B2
7618446 Andersen et al. Nov 2009 B2
7621948 Herrmann et al. Nov 2009 B2
7704222 Wilk et al. Apr 2010 B2
7736327 Wilk et al. Jun 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7753949 Lamphere et al. Jul 2010 B2
7806919 Bloom et al. Oct 2010 B2
7824443 Salahieh et al. Nov 2010 B2
7837727 Goetz et al. Nov 2010 B2
7892281 Seguin et al. Feb 2011 B2
7914569 Nguyen et al. Mar 2011 B2
7914575 Guyenot et al. Mar 2011 B2
7959672 Salahieh et al. Jun 2011 B2
7972378 Tabor et al. Jul 2011 B2
7981151 Rowe Jul 2011 B2
7993392 Righini et al. Aug 2011 B2
7993394 Hariton et al. Aug 2011 B2
8007992 Tian et al. Aug 2011 B2
8016877 Seguin et al. Sep 2011 B2
8029556 Rowe Oct 2011 B2
8052750 Tuval et al. Nov 2011 B2
8070800 Lock et al. Dec 2011 B2
8070802 Lamphere et al. Dec 2011 B2
8075615 Eberhardt et al. Dec 2011 B2
8080054 Rowe Dec 2011 B2
8092520 Quadri Jan 2012 B2
8092521 Figulla et al. Jan 2012 B2
8109996 Stacchino et al. Feb 2012 B2
8118866 Herrmann et al. Feb 2012 B2
8136218 Millwee et al. Mar 2012 B2
8137398 Tuval et al. Mar 2012 B2
8157852 Bloom et al. Apr 2012 B2
8167932 Bourang et al. May 2012 B2
8167934 Styrc et al. May 2012 B2
8182530 Huber May 2012 B2
8206437 Bonhoeffer et al. Jun 2012 B2
8216174 Wilk et al. Jul 2012 B2
8216301 Bonhoeffer et al. Jul 2012 B2
8219229 Cao et al. Jul 2012 B2
8220121 Hendriksen et al. Jul 2012 B2
8236045 Benichou et al. Aug 2012 B2
8246675 Zegdi Aug 2012 B2
8246678 Salahieh et al. Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8252052 Salahieh et al. Aug 2012 B2
8287584 Salahieh et al. Oct 2012 B2
8313525 Tuval et al. Nov 2012 B2
8317858 Straubinger et al. Nov 2012 B2
8323335 Rowe et al. Dec 2012 B2
8337541 Quadri et al. Dec 2012 B2
8353953 Giannetti et al. Jan 2013 B2
8398704 Straubinger et al. Mar 2013 B2
8403983 Quadri et al. Mar 2013 B2
8414644 Quadri et al. Apr 2013 B2
8414645 Dwork et al. Apr 2013 B2
8416643 Magee Apr 2013 B2
8444689 Zhang May 2013 B2
8449599 Chau et al. May 2013 B2
8454685 Hariton et al. Jun 2013 B2
8460368 Taylor et al. Jun 2013 B2
8460370 Zakay et al. Jun 2013 B2
8470023 Eidenschink et al. Jun 2013 B2
8470028 Thornton et al. Jun 2013 B2
8475521 Suri et al. Jul 2013 B2
8475523 Duffy Jul 2013 B2
8479380 Malewicz et al. Jul 2013 B2
8491650 Wiemeyer et al. Jul 2013 B2
8500733 Watson Aug 2013 B2
8500798 Rowe et al. Aug 2013 B2
8511244 Holecek et al. Aug 2013 B2
8512401 Murray et al. Aug 2013 B2
8518096 Nelson Aug 2013 B2
8518106 Duffy et al. Aug 2013 B2
8562663 Mearns et al. Oct 2013 B2
8579963 Tabor Nov 2013 B2
8579964 Lane et al. Nov 2013 B2
8591570 Revuelta et al. Nov 2013 B2
8617236 Paul et al. Dec 2013 B2
8640521 Righini et al. Feb 2014 B2
8647381 Essinger et al. Feb 2014 B2
8652145 Maimon et al. Feb 2014 B2
8652201 Oberti et al. Feb 2014 B2
8652202 Alon et al. Feb 2014 B2
8652203 Quadri et al. Feb 2014 B2
8668733 Haug et al. Mar 2014 B2
8679174 Ottma et al. Mar 2014 B2
8679404 Liburd et al. Mar 2014 B2
8685086 Navia et al. Apr 2014 B2
8721708 Sèguin et al. May 2014 B2
8721714 Kelley May 2014 B2
8728154 Alkhatib May 2014 B2
8728155 Montorfano et al. May 2014 B2
8740974 Lambrecht et al. Jun 2014 B2
8740976 Tran et al. Jun 2014 B2
8747458 Tuval et al. Jun 2014 B2
8747459 Nguyen et al. Jun 2014 B2
8758432 Solem Jun 2014 B2
8764818 Gregg Jul 2014 B2
8771344 Tran et al. Jul 2014 B2
8778020 Gregg et al. Jul 2014 B2
8784337 Voeller et al. Jul 2014 B2
8784478 Tuval et al. Jul 2014 B2
8784481 Alkhatib et al. Jul 2014 B2
8790387 Nguyen et al. Jul 2014 B2
8795357 Yohanan et al. Aug 2014 B2
8808356 Braido et al. Aug 2014 B2
8828078 Salahieh et al. Sep 2014 B2
8828079 Thielen et al. Sep 2014 B2
8834564 Tuval et al. Sep 2014 B2
8858620 Salahieh et al. Oct 2014 B2
8870948 Erzberger et al. Oct 2014 B1
8870950 Hacohen Oct 2014 B2
8876893 Dwork et al. Nov 2014 B2
8911455 Quadri et al. Dec 2014 B2
8926693 Duffy et al. Jan 2015 B2
8926694 Costello Jan 2015 B2
8939960 Rosenman et al. Jan 2015 B2
8945209 Bonyuet et al. Feb 2015 B2
8961593 Bonhoeffer et al. Feb 2015 B2
8961595 Alkhatib Feb 2015 B2
8974524 Yeung et al. Mar 2015 B2
8979922 Jayasinghe et al. Mar 2015 B2
8986375 Garde et al. Mar 2015 B2
8998980 Shipley et al. Apr 2015 B2
9005273 Salahieh et al. Apr 2015 B2
9011521 Haug et al. Apr 2015 B2
9011523 Seguin Apr 2015 B2
9011524 Eberhardt Apr 2015 B2
9028545 Taylor May 2015 B2
9034032 McLean et al. May 2015 B2
9055937 Rowe et al. Jun 2015 B2
9066801 Kovalsky et al. Jun 2015 B2
9078749 Lutter et al. Jul 2015 B2
9078751 Naor Jul 2015 B2
9125738 Figulla et al. Sep 2015 B2
9173737 Hill et al. Nov 2015 B2
9180004 Alkhatib Nov 2015 B2
9186249 Rolando et al. Nov 2015 B2
9277990 Klima et al. Mar 2016 B2
9277993 Gamarra et al. Mar 2016 B2
9289291 Gorman et al. Mar 2016 B2
9295551 Straubinger et al. Mar 2016 B2
9445897 Bishop et al. Sep 2016 B2
9456877 Weitzner et al. Oct 2016 B2
9681968 Goetz et al. Jun 2017 B2
9687345 Rabito et al. Jun 2017 B2
9700329 Metzger et al. Jul 2017 B2
9700411 Klima et al. Jul 2017 B2
9724083 Quadri et al. Aug 2017 B2
9730790 Quadri et al. Aug 2017 B2
9730791 Ratz et al. Aug 2017 B2
9795479 Lim et al. Oct 2017 B2
9833313 Board et al. Dec 2017 B2
9861473 Lafontaine Jan 2018 B2
9861476 Salahieh et al. Jan 2018 B2
9861477 Backus et al. Jan 2018 B2
9867698 Kovalsky et al. Jan 2018 B2
9877830 Lim et al. Jan 2018 B2
9889029 Li et al. Feb 2018 B2
9895225 Rolando et al. Feb 2018 B2
9925045 Creaven et al. Mar 2018 B2
10004599 Rabito et al. Jun 2018 B2
10117744 Ratz et al. Nov 2018 B2
10179044 Ratz et al. Jan 2019 B2
10219897 Essinger et al. Mar 2019 B2
10350065 Quadri Jul 2019 B2
10350066 Cooper et al. Jul 2019 B2
10376363 Quadri et al. Aug 2019 B2
10555809 Hastings et al. Feb 2020 B2
10575951 Johnson et al. Mar 2020 B2
10583000 Ratz et al. Mar 2020 B2
10639146 Quadri et al. May 2020 B2
10695177 Hariton et al. Jun 2020 B2
10758344 Hariton et al. Sep 2020 B2
11406499 Zhang et al. Aug 2022 B2
11452598 Essinger et al. Sep 2022 B2
11672658 Hariton et al. Jun 2023 B2
11701225 Hammer et al. Jul 2023 B2
11903829 Ma et al. Feb 2024 B1
20010021872 Bailey et al. Sep 2001 A1
20020032481 Gabbay Mar 2002 A1
20020045929 Diaz Apr 2002 A1
20020052644 Shaolian et al. May 2002 A1
20020173842 Buchanan Nov 2002 A1
20030050694 Yang et al. Mar 2003 A1
20030100939 Yodfat et al. May 2003 A1
20030105517 White et al. Jun 2003 A1
20030120333 Ouriel et al. Jun 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030158597 Quiachon et al. Aug 2003 A1
20030176914 Rabkin et al. Sep 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030212454 Scott et al. Nov 2003 A1
20030220683 Minasian et al. Nov 2003 A1
20040039436 Spenser et al. Feb 2004 A1
20040092858 Wilson et al. May 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040133263 Dusbabek et al. Jul 2004 A1
20040133273 Cox Jul 2004 A1
20040186563 Lobbi Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215325 Penn et al. Oct 2004 A1
20040225353 McGuckin et al. Nov 2004 A1
20040236411 Sarac et al. Nov 2004 A1
20040260389 Case et al. Dec 2004 A1
20050033398 Seguin Feb 2005 A1
20050075727 Wheatley Apr 2005 A1
20050090887 Pryor Apr 2005 A1
20050096738 Cali et al. May 2005 A1
20050107872 Mensah et al. May 2005 A1
20050137682 Justino Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050159811 Lane Jul 2005 A1
20050182486 Gabbay Aug 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050216079 MaCoviak Sep 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060020327 Lashinski et al. Jan 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060095115 Bladillah et al. May 2006 A1
20060142837 Haverkost et al. Jun 2006 A1
20060149350 Patel et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060173537 Yang et al. Aug 2006 A1
20060195134 Crittenden Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060212110 Osborne et al. Sep 2006 A1
20060229719 Marquez et al. Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060259135 Navia et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20060293745 Carpentier et al. Dec 2006 A1
20070005131 Taylor Jan 2007 A1
20070010877 Salahieh et al. Jan 2007 A1
20070027534 Bergheim et al. Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070050021 Johnson Mar 2007 A1
20070066863 Rafiee et al. Mar 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070100432 Case et al. May 2007 A1
20070100439 Cangialosi et al. May 2007 A1
20070112422 Dehdashtian May 2007 A1
20070129794 Realyvasquez Jun 2007 A1
20070142906 Figulla et al. Jun 2007 A1
20070156224 Cioanta et al. Jul 2007 A1
20070203503 Salahieh et al. Aug 2007 A1
20070203575 Forster et al. Aug 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070255394 Ryan Nov 2007 A1
20070270943 Solem et al. Nov 2007 A1
20080021546 Patz et al. Jan 2008 A1
20080065011 Marchand et al. Mar 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071362 Tuval et al. Mar 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080071366 Tuval et al. Mar 2008 A1
20080071368 Tuval et al. Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080082164 Friedman Apr 2008 A1
20080082165 Wilson et al. Apr 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080097581 Shanley Apr 2008 A1
20080114442 Mitchell et al. May 2008 A1
20080125853 Bailey et al. May 2008 A1
20080147179 Cai et al. Jun 2008 A1
20080147183 Styrc Jun 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080161910 Revuelta et al. Jul 2008 A1
20080177381 Navia et al. Jul 2008 A1
20080183273 Mesana et al. Jul 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080228254 Ryan Sep 2008 A1
20080255660 Guyenot et al. Oct 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080281411 Berreklouw Nov 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090054968 Bonhoeffer et al. Feb 2009 A1
20090054974 McGuckin et al. Feb 2009 A1
20090076598 Salahieh et al. Mar 2009 A1
20090112309 Jaramillo et al. Apr 2009 A1
20090138079 Tuval et al. May 2009 A1
20090157175 Benichou Jun 2009 A1
20090164005 Dove et al. Jun 2009 A1
20090171432 Von Segesser et al. Jul 2009 A1
20090171447 Von Segesser et al. Jul 2009 A1
20090171456 Kveen et al. Jul 2009 A1
20090182413 Burkart et al. Jul 2009 A1
20090188964 Orlov Jul 2009 A1
20090216310 Straubinger et al. Aug 2009 A1
20090216313 Straubinger et al. Aug 2009 A1
20090216322 Le et al. Aug 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090234443 Ottma et al. Sep 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090270972 Lane Oct 2009 A1
20090276027 Glynn Nov 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090281618 Hill et al. Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090287296 Manasse Nov 2009 A1
20090287299 Tabor et al. Nov 2009 A1
20090292350 Eberhardt et al. Nov 2009 A1
20090306768 Quadri Dec 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20100016958 St. Goar et al. Jan 2010 A1
20100024818 Stenzler et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100069852 Kelley Mar 2010 A1
20100114305 Kang et al. May 2010 A1
20100131054 Tuval et al. May 2010 A1
20100137979 Tuval et al. Jun 2010 A1
20100174362 Straubinger et al. Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100204781 Alkhatib Aug 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100249894 Oba et al. Sep 2010 A1
20100249911 Alkhatib Sep 2010 A1
20100256723 Murray Oct 2010 A1
20100262231 Tuval et al. Oct 2010 A1
20100305685 Millwee et al. Dec 2010 A1
20100312333 Navia et al. Dec 2010 A1
20110015616 Straubinger et al. Jan 2011 A1
20110015729 Jimenez et al. Jan 2011 A1
20110137397 Chau et al. Jun 2011 A1
20110178597 Navia et al. Jul 2011 A9
20110208290 Straubinger et al. Aug 2011 A1
20110208297 Tuval et al. Aug 2011 A1
20110208298 Tuval et al. Aug 2011 A1
20110224785 Hacohen Sep 2011 A1
20110238159 Guyenot et al. Sep 2011 A1
20110264196 Savage et al. Oct 2011 A1
20110264198 Murray et al. Oct 2011 A1
20110288634 Tuval et al. Nov 2011 A1
20110313515 Quadri et al. Dec 2011 A1
20110319989 Lane et al. Dec 2011 A1
20120022639 Hacohen et al. Jan 2012 A1
20120035722 Tuval Feb 2012 A1
20120041550 Salahieh et al. Feb 2012 A1
20120046741 Tuval et al. Feb 2012 A1
20120046742 Tuval et al. Feb 2012 A1
20120078360 Rafiee Mar 2012 A1
20120101570 Tuval et al. Apr 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120123529 Levi et al. May 2012 A1
20120185039 Tuval et al. Jul 2012 A1
20120197386 Von Segesser et al. Aug 2012 A1
20120209374 Bonhoeffer et al. Aug 2012 A1
20120215303 Quadri et al. Aug 2012 A1
20120271398 Essinger et al. Oct 2012 A1
20120283823 Bonhoeffer et al. Nov 2012 A1
20120290062 McNamara et al. Nov 2012 A1
20120296418 Bonyuet et al. Nov 2012 A1
20120310328 Olson et al. Dec 2012 A1
20120310336 Figulla et al. Dec 2012 A1
20130006294 Kashkarov et al. Jan 2013 A1
20130035759 Gross et al. Feb 2013 A1
20130073035 Tuval et al. Mar 2013 A1
20130079869 Straubinger et al. Mar 2013 A1
20130190861 Chau et al. Jul 2013 A1
20130190862 Pintor et al. Jul 2013 A1
20130197622 Mitra et al. Aug 2013 A1
20130211508 Lane et al. Aug 2013 A1
20130253635 Straubinger et al. Sep 2013 A1
20130253642 Brecker Sep 2013 A1
20130274595 Kermode Oct 2013 A1
20130310928 Morriss et al. Nov 2013 A1
20130331929 Mitra et al. Dec 2013 A1
20130338766 Hastings et al. Dec 2013 A1
20130345786 Behan Dec 2013 A1
20140018912 Delaloye et al. Jan 2014 A1
20140025163 Padala et al. Jan 2014 A1
20140039611 Lane et al. Feb 2014 A1
20140052237 Lane et al. Feb 2014 A1
20140100651 Kheradvar et al. Apr 2014 A1
20140163668 Rafiee Jun 2014 A1
20140172077 Bruchman et al. Jun 2014 A1
20140172083 Bruchman et al. Jun 2014 A1
20140194981 Menk et al. Jul 2014 A1
20140207231 Hacohen et al. Jul 2014 A1
20140214157 Börtlein et al. Jul 2014 A1
20140222136 Geist et al. Aug 2014 A1
20140222139 Nguyen et al. Aug 2014 A1
20140222142 Kovalsky et al. Aug 2014 A1
20140222144 Eberhardt et al. Aug 2014 A1
20140243966 Garde et al. Aug 2014 A1
20140257467 Lane et al. Sep 2014 A1
20140277390 Ratz et al. Sep 2014 A1
20140277403 Peter Sep 2014 A1
20140277412 Börtlein et al. Sep 2014 A1
20140277422 Ratz et al. Sep 2014 A1
20140277426 Dakin et al. Sep 2014 A1
20140277427 Ratz et al. Sep 2014 A1
20140296624 Kermode Oct 2014 A1
20140296973 Bergheim et al. Oct 2014 A1
20140296975 Tegels et al. Oct 2014 A1
20140303719 Cox et al. Oct 2014 A1
20140309728 Dehdashtian et al. Oct 2014 A1
20140324160 Benichou et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140330368 Gloss et al. Nov 2014 A1
20140330371 Gloss et al. Nov 2014 A1
20140330372 Weston et al. Nov 2014 A1
20140336754 Gurskis et al. Nov 2014 A1
20140343669 Lane et al. Nov 2014 A1
20140343670 Bakis et al. Nov 2014 A1
20140350666 Righini Nov 2014 A1
20140350668 Delaloye et al. Nov 2014 A1
20140358223 Rafiee et al. Dec 2014 A1
20140364939 Deshmukh et al. Dec 2014 A1
20140364941 Edmiston Dec 2014 A1
20140364943 Conklin Dec 2014 A1
20140371842 Marquez et al. Dec 2014 A1
20140371844 Dale et al. Dec 2014 A1
20140371847 Madrid et al. Dec 2014 A1
20140371848 Murray et al. Dec 2014 A1
20150005863 Para Jan 2015 A1
20150018944 O'Connell et al. Jan 2015 A1
20150039083 Rafiee Feb 2015 A1
20150142103 Vidlund May 2015 A1
20150148731 Mcnamara et al. May 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150196390 Ma et al. Jul 2015 A1
20150209141 Braido et al. Jul 2015 A1
20150272737 Dale et al. Oct 2015 A1
20150297346 Duffy et al. Oct 2015 A1
20150335429 Morriss et al. Nov 2015 A1
20150351903 Morriss et al. Dec 2015 A1
20150359629 Ganesan et al. Dec 2015 A1
20160000591 Lei et al. Jan 2016 A1
20160030169 Shahriari Feb 2016 A1
20160030170 Alkhatib et al. Feb 2016 A1
20160030171 Quijano et al. Feb 2016 A1
20160038281 Delaloye et al. Feb 2016 A1
20160074160 Christianson et al. Mar 2016 A1
20160106537 Christianson et al. Apr 2016 A1
20160113765 Ganesan et al. Apr 2016 A1
20160113768 Ganesan et al. Apr 2016 A1
20160143732 Glimsdale May 2016 A1
20160158010 Lim et al. Jun 2016 A1
20160166383 Lim et al. Jun 2016 A1
20160184097 Lim et al. Jun 2016 A1
20160199206 Lim et al. Jul 2016 A1
20160213473 Hacohen et al. Jul 2016 A1
20160235529 Ma et al. Aug 2016 A1
20160278923 Krans et al. Sep 2016 A1
20160279386 Dale et al. Sep 2016 A1
20160310267 Zeng et al. Oct 2016 A1
20170079785 Li Mar 2017 A1
20170128209 Morriss et al. May 2017 A1
20170216023 Lane et al. Aug 2017 A1
20170216575 Asleson et al. Aug 2017 A1
20170257902 Xing et al. Sep 2017 A1
20170258614 Griffin Sep 2017 A1
20170325945 Dale et al. Nov 2017 A1
20170325954 Perszyk Nov 2017 A1
20170333186 Spargias Nov 2017 A1
20170348096 Anderson Dec 2017 A1
20170367821 Landon et al. Dec 2017 A1
20170367823 Hariton et al. Dec 2017 A1
20180014931 Morriss et al. Jan 2018 A1
20180021129 Peterson et al. Jan 2018 A1
20180055629 Oba et al. Mar 2018 A1
20180055636 Valencia et al. Mar 2018 A1
20180085218 Eidenschink Mar 2018 A1
20180110534 Gavala et al. Apr 2018 A1
20180116790 Ratz et al. May 2018 A1
20180214664 Kim et al. Aug 2018 A1
20180344490 Fox et al. Dec 2018 A1
20190008639 Landon et al. Jan 2019 A1
20190008640 Cooper et al. Jan 2019 A1
20190060072 Zeng Feb 2019 A1
20190262129 Cooper et al. Aug 2019 A1
20200000579 Manash et al. Jan 2020 A1
20200108225 Jamal et al. Apr 2020 A1
20200138572 Zhao et al. May 2020 A1
20200323668 Diedering et al. Oct 2020 A1
20200345494 Srinimukesh et al. Nov 2020 A1
20200352718 Rowe et al. Nov 2020 A1
20210145576 Becerra et al. May 2021 A1
20210259835 Tyler, II et al. Aug 2021 A1
20210307900 Hacohen Oct 2021 A1
20210378817 Nia et al. Dec 2021 A1
20210386544 Cooper et al. Dec 2021 A1
20220142777 Scheinblum et al. May 2022 A1
20220287836 Landon et al. Sep 2022 A1
20220346993 Srinimukesh et al. Nov 2022 A1
20230000624 Okabe et al. Jan 2023 A1
20230200980 Peterson et al. Jun 2023 A1
20230218391 Dass et al. Jul 2023 A1
20230380963 Kaufman et al. Nov 2023 A1
20230390052 Okafor et al. Dec 2023 A1
20230404753 Luong et al. Dec 2023 A1
20240008978 Nawalakhe et al. Jan 2024 A1
20240091000 King et al. Mar 2024 A1
Foreign Referenced Citations (141)
Number Date Country
2304325 May 2008 CA
2246526 Mar 1973 DE
19532846 Mar 1997 DE
19546692 Jun 1997 DE
19857887 Jul 2000 DE
19907646 Aug 2000 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049814 Apr 2002 DE
10049815 Apr 2002 DE
10010074 Apr 2005 DE
102006052564 Dec 2007 DE
0144167 Jun 1985 EP
0103546 May 1988 EP
0592410 Oct 1995 EP
0850607 Jul 1998 EP
0597967 Dec 1999 EP
1057460 Dec 2000 EP
1088529 Apr 2001 EP
1469797 Oct 2004 EP
1259194 Feb 2005 EP
1171059 Nov 2005 EP
1255510 Apr 2007 EP
1239901 Oct 2007 EP
1849440 Oct 2007 EP
1570809 Jan 2009 EP
1472996 Sep 2009 EP
1653888 Sep 2009 EP
1935377 Mar 2010 EP
1369098 Apr 2014 EP
2124826 Jul 2014 EP
2745805 Jun 2015 EP
2749254 Jun 2015 EP
2918249 Sep 2015 EP
2168536 Apr 2016 EP
2413842 Aug 2017 EP
2446915 Jan 2018 EP
3057541 Jan 2018 EP
3037064 Mar 2018 EP
3046511 Mar 2018 EP
3142603 Mar 2018 EP
3075354 Nov 2018 EP
3184083 Feb 2019 EP
3417813 May 2020 EP
2777616 Aug 2020 EP
3139864 Nov 2020 EP
2750630 Jun 2021 EP
2777617 Sep 2022 EP
2948103 Dec 2022 EP
2967858 Jan 2023 EP
3570779 Feb 2023 EP
3294220 Dec 2023 EP
2788217 Jul 2000 FR
1264471 Feb 1972 GB
1315844 May 1973 GB
2056023 Mar 1981 GB
2398245 Aug 2004 GB
1271508 Nov 1986 SU
1991016041 Oct 1991 WO
1991017720 Nov 1991 WO
1992017118 Oct 1992 WO
1993001768 Feb 1993 WO
1997024080 Jul 1997 WO
1998029057 Jul 1998 WO
1999033414 Jul 1999 WO
1999040964 Aug 1999 WO
1999047075 Sep 1999 WO
2000018333 Apr 2000 WO
2000041652 Jul 2000 WO
2000047139 Aug 2000 WO
2000061034 Oct 2000 WO
2001028459 Apr 2001 WO
2001035878 May 2001 WO
2001049213 Jul 2001 WO
2001054624 Aug 2001 WO
2001054625 Aug 2001 WO
2001062189 Aug 2001 WO
2001064137 Sep 2001 WO
2001076510 Oct 2001 WO
2002036048 May 2002 WO
2003047468 Jun 2003 WO
2003092554 Nov 2003 WO
2004030569 Apr 2004 WO
2005011534 Feb 2005 WO
2005034812 Apr 2005 WO
2005087140 Sep 2005 WO
2005102015 Nov 2005 WO
2006014233 Feb 2006 WO
2006034008 Mar 2006 WO
2006085225 Aug 2006 WO
2006108090 Oct 2006 WO
2006111391 Oct 2006 WO
2006138173 Dec 2006 WO
2007025028 Mar 2007 WO
2008005405 Jan 2008 WO
2008035337 Mar 2008 WO
2008125153 Oct 2008 WO
2008147964 Dec 2008 WO
2008150529 Dec 2008 WO
2009024859 Feb 2009 WO
2009026563 Feb 2009 WO
2009042196 Apr 2009 WO
2009091509 Jul 2009 WO
2009094500 Jul 2009 WO
2010005524 Jan 2010 WO
2010008549 Jan 2010 WO
2010121076 Oct 2010 WO
2011002996 Jan 2011 WO
2011081997 Jul 2011 WO
2012032187 Mar 2012 WO
2012095455 Jul 2012 WO
2013028387 Feb 2013 WO
2013106585 Jul 2013 WO
2014018432 Jan 2014 WO
2014079291 May 2014 WO
2014145338 Sep 2014 WO
2014149865 Sep 2014 WO
2014163706 Oct 2014 WO
2014194178 Dec 2014 WO
2015057407 Apr 2015 WO
2015077274 May 2015 WO
2016016899 Feb 2016 WO
2017035487 Mar 2017 WO
2018213209 Nov 2018 WO
2022002054 Jan 2022 WO
2023006048 Feb 2023 WO
2023076103 May 2023 WO
2023081236 May 2023 WO
2023091769 May 2023 WO
2023096804 Jun 2023 WO
2023154250 Aug 2023 WO
2023196150 Oct 2023 WO
2023244454 Dec 2023 WO
2023244767 Dec 2023 WO
2023250114 Dec 2023 WO
2024001789 Jan 2024 WO
2024003620 Jan 2024 WO
2024007575 Jan 2024 WO
2024009540 Jan 2024 WO
2024010739 Jan 2024 WO
2024030520 Feb 2024 WO
Non-Patent Literature Citations (48)
Entry
Andersen, et al., “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.”European Heart Journal (1992), 13, 704-708.
Andersen, Henning Rud, “History of Percutaneous Aortic Valve Prosthesis,” Herz 34 2009 Nr. 5, Urban&Vogel, pp. 343-346, Skejby University Hospital Department of Cardiology, Aarhus, Denmark.
Dotter, M.D., Charles T., “Transluminal Treatment of Arteriosclerotic Obstruction,” University of Oregon's Minthorn Memorial Laboratory for Cardiovascular Research through Radiology, Circulation, vol. XXX, Nov. 1964, pp. 654-670.
Inoue, M.D., Kanji, et al., “Clinical Application of Transvenous Mitral Commissurotomy by a New Balloon Catheter,” The Journal of Thoracic and Cardiovascular Surgery 87:394-402, 1984.
Pavcnik, M.D., Ph.D., Dusan, et al. “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement,” Cardiovascular Radiology 1992; 183:151-154.
Rashkind, M.D., William J., “Historical Aspects of Interventional Cardiology: Past, Present, Future,” Texas Heart Institute Journal, Interventional Cardiology, pp. 363-367.
Rösch, M.D., Josef, “The Birth, Early Years and Future of Interventional Radiology,” J Vasc Interv Radiol 2003; 14:841-853.
Ross, F.R.C.S., D.N., “Aortic Valve Surgery,” Guy's Hospital, London, pp. 192-197, approximately 1968.
Sabbah, Ph.D., Hani N., et al., “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview,” Journal of Cardiac Surgery, vol. 4, No. 4, pp. 302-309, Dec. 1989; ISSN 0886-0440.
Wheatley, M.D., David J., “Valve Prostheses,” Rob&Smith's Operative Surgery, Fourth Edition, pp. 415-424, Butterworths 1986.
Bavaria, Joseph E. M.D. et al.: “Transcatheter Mitral Valve Implantation: The Future Gold Standard for MR?”.
Backer, Ole De, MD, et al., “Percutaneous Transcatheter Mitral Valve Replacement—An Overview of Devices in Preclinical and Early Clinical Evaluation,” Contemporary Reviews in Interventional Cardiology, Circ Cardiovasc Interv. 2014;7:400-409.
Bavaria, Joseph E. M.D.: “CardiAQ Valve Technologies: Transcatheter Mitral Valve Implantation,” Sep. 21, 2009.
Berreklouw, Eric, PhD, et al., “Sutureless Mitral Valve Replacement With Bioprostheses and Nitinol Attachment Rings: Feasibility In Acute Pig Experiments,” The Journal of Thoracic and Cardiovascular Surgery, vol. 142, No. 2, Aug. 2011 in 7 pages.
Boudjemline, Younes, et al., “Steps Toward the Percutaneous Replacement of Atrioventricular Valves,” JACC, vol. 46, No. 2, Jul. 19, 2005:360-5.
CardiAQ Valve Technologies, “Innovations in Heart Valve Therapy,” In3 San Francisco, Jun. 18, 2008, PowerPoint presentation in 19 slides.
Chiam, Paul T.L., et al., “Percutaneous Transcatheter Aortic Valve Implantation: Assessing Results, Judging Outcomes, and Planning Trials,” JACC: Cardiovascular Interventions, The American College of Cardiology Foundation, vol. 1, No. 4, Aug. 2008:341-50.
Condado, Jose Antonio, et al., “Percutaneous Treatment of Heart Valves,” Rev Esp Cardio. 2006;59(12):1225-31.
Feldman, Ted, MD. “Prospects for Percutaneous Valve Therapies,” Circulation 2007;116:2866-2877.
Fitzgerald, Peter J. M.D., “Tomorrow's Technology: Percutaneous Mitral Valve Replacement, Chordal Shortening, and Beyond,” Transcatheter Valve Therapies (TVT) Conference. Seattle, WA.
Fornell, Dave, “Transcatheter Mitral Valve replacement Devices in Development,” Diagnostic and Interventional Cardiology, Dec. 30, 2014, p. 3, <http://www.dicardiology.com/article/transcatheter-mitral-valve-replacement-devices-development>.
Grube, E. et al., “Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome.” J Am Coll Cardiol. Jul. 3, 2007;50(1):69-76. Epub Jun. 6, 2007.
Karimi, Houshang, et al., “Percutaneous Valve Therapies,” SIS 2007 Yearbook, Chapter 11, pp. 1-11.
Kronemyer, Bob, “CardiAQ Valve Technologies: Percutaneous Mitral Valve Replacement,” Start Up—Windhover Review of Emerging Medical Ventures, vol. 14, Issue No. 6, Jun. 2009, pp. 48-49.
Leon, Martin B., et al., “Transcatheter Aortic Valve Replacement in Patients with Critical Aortic Stenosis: Rationale, Device Descriptions, Early Clinical Experiences, and Perspectives,” Semin. Thorac. Cardiovasc. Surg. 18:165-174, 2006 in 10 pages.
Lutter, Georg, et al., “Off-Pump Transapical Mitral Valve Replacement,” European Journal of Cardio-thoracic Surgery 36 (2009) 124-128.
Ma, Liang, et al., “'Double-Crowned Valved Stents For Off-Pump Mitral Valve Replacement,” European Journal of Cardio-thoracic Surgery 28 (2005) 194-199.
Mack, Michael, M.D., “Antegrade Transcatheter Mitral valve Implantation: A Short-term Experience in Swine Model.”
Mack, Michael, M.D., “Antegrade Transcatheter Mitral valve Implantation: On-Going Experience in Swine Model.”
Ostrovsky, Gene, “Transcatheter Mitral Valve Implantation Technology from CardiAQ,” medGadget, Jan. 15, 2010, available at: http://www.medgadget.com/2010/01/transcatheter_mitral_valve_implantation_technology_from_cardiaq.html.
Preston-Maher, Georgia L., et al., “A Technical Review of Minimally Invasive Mitral Valve Replacements,” Cardiovascular Engineering and Technology, vol. 6, No. 2, Jun. 2015, pp. 174-184.
Quadri, Arshad M.D., “Transcatheter Mitral Valve Implantation (TMVI) (An Acute In Vivo Study).”
Ratz, J. Brent, “LSI EMT Spotlight,” May 15, 2009.
Ratz, J. Brent et al., “Any experiences making an expandable stent frame?” Arch-Pub.com, Architecture Forums: Modeling, Multiple forum postings from Feb. 3, 2009 to Feb. 4, 2009, http://www.arch-pub.com.
Ratz, J. Brent, “In3 Company Overview,” Jun. 24, 2009.
Ruiz, Carlos E., “Overview of Novel Transcatheter Valve Technologies.”
Spillner, J. et al., “New Sutureless ‘Atrial-Mitral-Valve Prosthesis’ For Minimally Invasive Mitral Valve Therapy,” Textile Research Journal, 2010, in 7 pages.
Sondergaard, Lars, et al., “Transcatheter Mitral Valve Implantation: CardiAQ™,” TCT 2013.
Sondergaard, Lars, et al., “Transcatheter Mitral Valve Implantation: CardiAQ™,” EuroPCR 2013.
Sondergaard, Lars, “CardiAQ TMVR FIH—Generation 2,” TVT symposium.
Treede et al.: “Transapical transcatheter aortic valve implantation using the JenaValve™ system: acute and 30-day results of the multicentre CE-mark study.” http://ejcts.oxfordjournals.org/content/41/6/e131.long. Apr. 16, 2012.
Taramasso et al.: “New devices for TAVI: technologies and initial clinical experiences” http://www.nature.com/nrcardio/journal/v11/n3/full/nrcardio.2013.221.html?message-global=remove#access. Jan. 21, 2014.
Webb, John G., et al., “Transcatheter Aortic Valve Implantation: The Evolution Of Prostheses, Delivery Systems And Approaches,” Archives of Cardiovascular Disease (2012) 105, 153-159.
Wayback Machine, Cleveland Clinic Lerner Research Institute, Transcatheter Mitral Stent/Valve Prosthetic, https://web.archive.org/web/20130831094624/http://mds.clevelandclinic.org/Portfolio.aspx?n=331, indicated as archived on Aug. 31, 2013.
“CardiAQ Valve Technologies, Percutaneous Mitral Valve Replacement, Company Overview,” at TVT on Jun. 25, 2009.
BioSpace, “CardiAQ Valve Technologies (CVT) Reports First-In-Human Percutaneous Transfemoral, Transseptal Implantation With Its Second Generation Transcatheter Bioprosthetic Mitral Heart Valve,” Jun. 23, 2015, p. 1, http://www.biospace.com/News/cardiaq-valve-technologies-cvt-reports-first- in/382370.
BioSpace, “CardiAQ Valve Technologies (CVT) Reports Cardiovascular Medicine Milestone: First-In-Humannonsurgical Percutaneous Implantation of a Bioprosthetic Mitral Heart Valve,” Jun. 14, 2012, p. 1, http://www.biospace.com/News/cardiaq-valve-technologies-cvt-reports/263900.
Neovasc corporate presentation, Oct. 2009, available at http://www.neovasc.com/investors/documents/Neovasc-Corporate-Presentation-October-2009.pdf.
Related Publications (1)
Number Date Country
20240099722 A1 Mar 2024 US
Provisional Applications (1)
Number Date Country
62136248 Mar 2015 US
Divisions (1)
Number Date Country
Parent 15559680 US
Child 16997793 US
Continuations (1)
Number Date Country
Parent 16997793 Aug 2020 US
Child 18530731 US